n Cardiovascular Journal of South Africa - EC approves irbesartan for the treatment of diabetic renal disease : drug trends in cardiology
|Article Title||EC approves irbesartan for the treatment of diabetic renal disease : drug trends in cardiology|
|© Publisher:||Clinics Cardive Publishing|
|Journal||Cardiovascular Journal of South Africa|
|Publication Date||Jul 2002|
|Pages||216 - 217|
Extracted from text ... EC approves irbesartan for the treatment of diabetic renal disease. BristolMyers Squibb Company (NYSE: BMY) and SanofiSynthelabo (Paris Bourse: Sicovam code 12057) have announced that the European Commission has approved irbesartan (Aprove?/Karve?) in the European Union for a new indication: the treatment of renal disease in people with hypertension and type 2 diabetes mellitus (as part of a antihypertensive drug regimen). Irbesartan is the first blood pressurelowering drug approved across the European Union for treatment of both early and latestage diabetic renal disease in hypertensive type 2 diabetic patients. Irbesartan, an angiotensin II receptor antagonist (AIIRA), is already indicated for ..
Article metrics loading...